Botanical Supplement Muscle Function and Lean Body Mass

September 17, 2018 updated by: University of North Carolina, Chapel Hill

The Acute and Chronic Influence of a Botanical Supplement on Muscle Function and Lean Body Mass

Purpose: To evaluate the acute and chronic effects of a botanical supplement on strength, muscle function, and lean body mass

Participants: The acute phase will include 30 participants, and the chronic phase will include 84 participants. All participants must be healthy recreationally active males between the ages of 18 and 35 years.

Procedures (methods):

Acute phase: Participants will complete three testing visits as part of as part of a cross-over design, during which strength and muscle function will be assessed prior to and following consumption of a supplement. The experimental supplement is a blend of the botanical extracts; treatment arms will include a full dose (FULL; 350 mg capsule), half dose (HALF; 175 mg plus maltodextrin), or placebo (PLA; maltodextrin).

Chronic phase: Body composition, muscle cross-sectional area, a complete blood count and metabolic panel, subjective surveys, and strength will be measured prior to and following an 8-week supervised resistance training program, in conjunction with daily supplementation of FULL, HALF, or PLA.

Study Overview

Study Type

Interventional

Enrollment (Actual)

119

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • University of North Carolina, Department of Exercise and Sport Science

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Recreationally Active (1- 4 hours of exercise/ sports participation per week and no more than 1 hour of resistance training exercise per week) for the previous 12 weeks.
  • BMI < 30 kg/m²
  • Have not smoked in the past year.
  • Participant has provided written and dated informed consent to participate in the study
  • Participant is willing and able to comply with the protocol
  • Participant is apparently healthy and free from disease, as determined by a health history questionnaire
  • Participant agrees to abstain from caffeine, tobacco, alcohol, and exercise within 24 hours of testing visits

Exclusion Criteria:

  • Participant has not used any dietary supplements within 12 weeks prior to enrollment and will not begin supplementation during the study. Potential supplements include but are not limited to Beta-alanine, Creatine, HMB, Carnosine, Taurine, androstenedione, DHEA, Whey protein, or a pre-workout supplement.
  • Participant has gained or lost 10 lbs in the previous 2 months.
  • Participant is currently enrolled in a separate clinical trial.
  • Participant has participated in a clinical trial within the previous 2 months that includes modifications to their physical and/or diet.
  • Participant has a known allergy or sensitivity to the placebo (maltodextrin) or active ingredients (Rhodiola & Rhaptonicum)
  • Participant consumes more than 8 cups (1 cup = 6 oz) of coffee per day on a regular basis
  • Participant consumes more than 3 alcoholic drinks per day.
  • Participant uses recreational drugs daily.
  • Previous physical symptoms causing a physician to recommend you to refrain from exercise.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Maltodextrin
Maltodextrin: 350 mg
Experimental: CS16-003 Full dose
350 mg capsule QD Rhodiola rosea L. & Rhaptonticum carthamoides extracts
350 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts
Experimental: CS16-003 Half dose
175 mg capsule QD 50% Rhodiola rosea L. & Rhaptonticum carthamoides extracts + 50% Maltodextrin
175 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts + maltodextrin 175 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Maximal Isokinetic Leg Extension strength measured by dynamometry
Time Frame: Acute/Immediate
Acute/Immediate
Maximal Upper and Lower Body Strength measured by 1 repetition maximum
Time Frame: 8 weeks
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bench Press Repetitions to Fatigue
Time Frame: 8 weeks
8 weeks
Leg Press Repetitions to Fatigue
Time Frame: 8 weeks
8 weeks
Body Composition-Lean Mass
Time Frame: 8 weeks
8 weeks
Body Composition-Fat Mass
Time Frame: 8 weeks
8 weeks
Muscle cross sectional area
Time Frame: 8 weeks
8 weeks
Change in Quality of Life Score from baseline to 8 weeks
Time Frame: baseline, 8 weeks
Quality of life from a visual analog scale (VAS) 0-100, with 0 = worst quality of life and 100=best quality of life.
baseline, 8 weeks
Change in Felt Arousal score from baseline to 8 weeks
Time Frame: baseline, 8 weeks
Felt arousal scale. Scores range 1-6 with 1 being low arousal and 6 being high. One score selected.
baseline, 8 weeks
Change in Mood score from baseline to 8 weeks
Time Frame: baseline; 8 weeks
Mood determined from a VAS. 0-100, with 0 = not depressed at all and 100 = most depressed.
baseline; 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Eric Ryan, PhD, University of North Carolina, Chapel Hill

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2016

Primary Completion (Actual)

August 1, 2018

Study Completion (Actual)

August 1, 2018

Study Registration Dates

First Submitted

January 17, 2017

First Submitted That Met QC Criteria

January 24, 2017

First Posted (Estimate)

January 27, 2017

Study Record Updates

Last Update Posted (Actual)

September 18, 2018

Last Update Submitted That Met QC Criteria

September 17, 2018

Last Verified

September 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 16-1991

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteers

Clinical Trials on CS16-003 Full dose

3
Subscribe